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Yuanyuan Wang1, Zhen Li1, Zhengyan Jiang1, Xingxing Liu5, Lijuan Zhang5, Dongmei Zuo5,
Zhexing Shou5, Qing Tang5, Huisuo Huang7, Yongqiang Yang7, Zongxiang Tang6 & Jun Xiao7*
Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder significantly decreasing
patients’ lives of quality and placing huge economic burden on our society. Existing studies indicated
that the therapeutic effects maintained for a period of time after the treatments were discontinued.
It is clinically important to assess these post-treatment therapeutic effects (PTTE), which prevent IBS
from relapsing. To assess the PTTE in pinaverium treatment and obtain high-quality evidence to justify
the use of PTTE for long-term IBS management, we performed this controlled, double blind study on
patients with IBS who were randomized to pinaverium 50 mg (n = 132) or placebo (n = 132), three times
daily, for 4 weeks, and were followed up for 57 weeks after the treatments. The primary endpoints
were abdominal pain and stool consistency. The secondary endpoints were pain frequency and stool
frequency. The tertiary endpoints were global overall symptom and adverse events. Three days after
pinaverium was discontinued, endpoints rebounded only 23.2–42.8% (P < 0.015 cf. placebo). The
PTTE (P < 0.05 cf. placebo) lasted 9–17 weeks, which is similar to other antispasmodics with a 15-week
treatment in striking contrast to ≥ 1 year PTTE in cognitive behavior therapy and < 1 week PTTE in
serotonin antagonist treatment indicating that PTTE length markedly depends on the medication
class used for the treatment and less depends on treatment length. After 17 weeks, the stage could
be considered as an IBS natural history [no significant differences between pinaverium and placebo
(all endpoints’ P’s > 0.05)], during which an average of 51.5–56.4% of patients (pool pinaverium and
placebo data together) had IBS symptoms. These results provide clinical insights into efficient and
cost-effective management of refractory IBS, and lend support to the IBS management that the
selection of a therapy should consider both its effectiveness during treatment and its PTTE after the
treatment.
Trial registration number: NCT02330029 (16/08/2016).
Abbreviations
5-HT3	5-Hydroxytryptamine
CBT	Cognitive behavior therapy
IBS	Irritable bowel syndrome
PTTE	Post-treatment therapeutic effects
RR	Relative risk
1

Department of Gastroenterology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine,
23 Nanhu Rd, Nanjing 210017, China. 2Department of Internal Medicine, Jiangsu Provincial Hospital of Chinese
Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Rd., Nanjing 210029,
China. 3The School of Medicine, Washington University, 660 S Euclid Ave., St. Louis, MO 63110, USA. 4Department
of Gastroenterology, Beijing Xuanwu Hospital of Chinese Medicine, 8 Wanming Rd., Beijing 100050,
China. 5Department of Integrated Chinese Medicine and Western Medicine, Union Hospital, Tongji Medical
College, Huazhong University of Science and Technology, 1277 Liberty Rd., Wuhan 430022, China. 6The State
Key Laboratory Cultivation Base for TCM Quality and Efficacy, The School of Medicine and Life Sciences, Nanjing
University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China. 7The Macrohard Institute of Health, 231
North Ave., Battle Creek, MI 49017, USA. *email: jxiao@macrohardinstitute.org
Scientific Reports |

(2021) 11:13894

| https://doi.org/10.1038/s41598-021-92990-7

1
Vol.:(0123456789)

www.nature.com/scientificreports/
Irritable bowel syndrome (IBS) is the most common chronic and a highly relapsing gastrointestinal disorder
with an estimated worldwide prevalence of 10–15%1. More than 50% of patients were still symptomatic with
IBS, and a further 25% of the patients had minor IBS symptoms after 1 and 7 y ears2. For many patients, IBS is
a lifelong c ondition3. Therefore, how to prevent IBS from relapsing after the treatment is equally important to
how effective the therapy is during the treatment.
Existing studies showed that the therapeutic effects maintained for a period of time after the treatments were
discontinued, or IBS treatments have post-treatment therapeutic effects (PTTE) that prevent the recurrence of
IBS4. However, only a few studies investigated the PTTE (Supplemental Material Table S1); very few studies
followed up with patients after PTTE disappeared (Table S2); and no studies have been specifically designed to
assess PTTE. In particular, of the 188 randomized controlled trials reviewed by the American College of Gastroenterology, only 31 trials collected outcome data after treatments and compared the post-treatment data with
those of a placebo/control5. And although these studies collected post-treatment data, they were not intended to
investigate the PTTE. Some studies’ post-treatment follow-up duration were too short to cover the entire PTTE
(trail # 1, 3, 5–20, 23–25 in Table S2). Cappello et al. and Vahedi et al. showed that the PTTE was still significant
(P < 0.05) at week 4 after treatment, but no data were collected after week 4 so that the accurate length of PTTE
was still unknown6,7. The most accurate conclusion we could draw from this study was that the PTTE length was
4 weeks or longer. Some studies only collected post-treatment data 1 year later (trail # 21) or 6 months later (trail
# 22) while no data were collected in between. This data collection resolution was too low to accurately identify
the PTTE length. For example, the PTTE length of paroxetine in the study by Creed et al. could be anywhere
from < 1 week to 11 months because Creed et al. only collected the post-treatment data 1 year after the therapy
was discontinued8.
Nevertheless, the preliminary data from existing studies interestingly showed that the length of PTTE markedly depended on the types of treatment (“treatment-dependent PTTE”) (Table S2). Cognitive behavior therapy
(CBT) had the longest PTTE (roughly one year or longer), while 5-hydroxytryptamine (5-HT3) antagonist,
alosetron, the shortest (less than one week), and antidepressants had 4 weeks to 1 year P
 TTE7–11. Strikingly
remarkable is that in CBT, the PTTE length less depends on the treatment length, who administered the treatment, and how the treatment was administered. Heitkemper et al. demonstrated that 8 weekly 1-h sessions selfmanagement CBT (Comprehensive group) had a similar PTTE length to one 90-min session self-management
CBT (Brief group) that covered the same material as the Comprehensive group9. Lackner et al. showed that 10
session therapist-administered CBT and 4 session self-administered CBT had similar lengths of PTTE10. Everitt
et al. demonstrated that telephone-CBT and web-CBT had similar lengths of P
 TTE11. Jarrett et al. showed that
CBT delivered in-person and CBT delivered via telephone had similar lengths of P
 TTE12. All these results provide
clinically and socially important insight into cost-effective long-term management of refractory IBS.
PTTE is increasingly recognised as being valuable for decreasing the recurrence of I BS13. To accurately assess
PTTE, a study should (1) test simultaneously whether the treatment is effective when compared with a placebo,
(2) follow up with patients for a period that is long enough to cover both the PTTE period, if any, and the IBS
natural history thereafter, (3) collect data at an adequate resolution. This study satisfies this 3-element criterion.
Antispasmodics are one of the common IBS m
 edications14. Clavé et al. showed that patients on otilonium
for 15 weeks benefited from a 10-week or more PTTE15. Pinaverium is one of the most commonly used IBS
medications worldwide16–22. Our previous study demonstrated that pinaverium for 4 weeks effectively relieved
IBS symptoms16. To further investigate the PTTE of this pharmacological therapy, the relapse-free probability,
and the IBS natural history after the PTTE, this study collected post-treatment data on days 1, 2, and 3, at weeks
4, 9, 17, 25, 33, 45, and 57.

Methods

Trial design and settings. This study was conducted at four hospitals in China from December 2016 to

June 2019. The protocol was approved by the Institutional Review Board of each participating hospital and by the
Ethics Committee of the Macrohard Institute of Health. The Institutional Review Board guidelines for clinical
research were strictly followed. Research staff recruited potential participants, and explained the purpose and
eligibility requirements of the study to them. Written consent was obtained from each subject prior to enrollment. A questionnaire regarding patients’ medical history was administered (Table S3). This study consisted of
2 weeks of run-in, 4 weeks of treatment, and 57 weeks of follow-up.

Diagnosis, inclusion, and exclusion criteria. Subjects who were diagnosed with diarrhea-predominant
IBS by the Rome IV criteria were eligible for enrollment. Specifically, patients had recurrent abdominal pain
on average at least 1 day/week during the previous 3 months that is associated with 2 or more of the following:
(a) related to defecation, (b) associated with a change in stool frequency, and/or (c) associated with a change in
stool appearance. The criterion was fulfilled for the last 3 months with symptom onset at least 6 months prior to
diagnosis. The inclusion criteria and exclusion criteria were described in our previous t rial16.
Randomization and blinding. The permuted block randomization sequence was computer generated

with a block size of six. The sequence was concealed in an opaque envelope, and was kept by the independent
assistants at each participating hospital until the treatment was assigned. All investigators were blinded to the
randomization sequence. After obtaining written consents from eligible subjects, the study nurses contacted
the independent assistants to obtain an envelope, which contained the allocation information. Eligible subjects
were randomized to receive pinaverium, 50 mg tablets, or placebo, which was visually identical in appearance to
pinaverium. Both were taken three times daily for 4 weeks.
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Study outcomes.

The primary and secondary endpoints recommended by the US Food and Drug Administration for IBS were used in this study23. Briefly, the primary endpoints were the average of pain intensity
(0 = no pain, 10 = worst pain) and stool consistency (Bristol stool form scale) in the worst day of the 30 days
before treatment (baseline), or of the days between last follow-up and the current follow-up (treatment and posttreatment). The secondary endpoints (scale 0–10) included the averages of daily frequencies of abdominal pain
and stool. A clinical responder was defined previously16,23.
The tertiary endpoints were adverse events and IBS global overall symptom scale23, which was evaluated
based on the answer to the question “how would you overall rate your IBS symptoms today?” Zero indicates
no symptoms; 1 indicates minimum symptoms; 2 indicates mild symptoms; 3 indicates moderate symptoms; 4
indicates severe symptoms.
The above clinical data were collected before treatment (baseline), during treatment (days 1, 2, and 3, weeks
1 and 4), and after treatment (days 1, 2, and 3, weeks 4, 9, 17, 25, 33, 45, and 57). A bowel symptom scale table
containing the above endpoint questionnaires was developed for the trial (Table S4).

Statistical analysis. Categorical data were compared using the Chi-square test. Continuous data were

expressed as mean ± standard deviation and compared using the Student’s t test. The sample size was estimated
using power calculation (see the Supplemental Materials). All p values were two-tailed with the level of statistical significance set at 0.05. The primary efficacy analysis included a comparison of the response rates between
pinaverium and placebo. Pearson product moment correlation or the Average Inter-item Correlation ( r∑) analyses were used to test the correlation among the primary endpoints, the secondary endpoints, and the global
overall symptom scale. Logrank Tests (Kaplan–Meier Curves) were used for survival (relapse-free) analysis. All
authors had access to the study data, and reviewed and approved the final manuscript.

Results

Patient populations and baseline characteristics. A total of 402 patients were screened for this study

(Fig. 1). Two hundred sixty-four patients were randomized to either take pinaverium or placebo. The intentto-treat population consisted of 132 patients taking pinaverium and placebo, respectively, which were analyzed
further. Baseline characteristics of the two groups showed no significant difference (P > 0.05) (Table 1).

Primary and secondary outcomes during the treatment. The onset of action. Pinaverium significantly and rapidly reduced the scales of the primary and secondary endpoints from day 1 (P < 0.05; Fig. 2; Tables S5 and S6). The decreases in the scales during the first 3 days accounted for 88.7% (pain intensity), 75.5%
(stool consistency), 94.5% (pain frequency), and 77.6% (stool frequency) of the total decreases, respectively,
[(Baseline − Day 3)/(Baseline − Week 4)] indicating that pinaverium relieved pain more quickly than improved
stool consistency. No symptoms were significantly improved further after 1 week (P = 0.15–0.85) although the
symptom scales still decreased after 1 week in the pinaverium group. These results indicate that pinaverium has
a rapid onset of action for relieving IBS symptoms.
The efficacy of the treatment. Significantly more patients in the pinaverium group were clinical responders
to the primary and secondary endpoints when compared with placebo (Table 2, P < 0.05–0.001). In particular,
pinaverium relieved pain in 52.3%, 54.5%, 60.6%, 53.8%, and 64.4% of patients on days 1, 2, and 3, at weeks 1 and
4 while placebo in 17.4%, 23.5%, 29.5%, 30.3%, and 31.8% of the patients; pinaverium improved stool consistency in 28.8%, 31.8%, 37.9%, 47.7%, and 54.5% of patients on days 1, 2, and 3, at weeks 1 and 4 while placebo in
12.9%, 14.4%, 15.9%, 28.8%, and 31.8% of the patients.
The relative risks (RRs) for pain scale > 3 in patients of the pinaverium group were 0.74 (95% CI, 0.66–0.83),
0.74 (0.65–0.84), 0.70 (0.61–0.81), 0.70 (0.60–0.81), and 0.61 (0.51–0.72) when compared with placebo on days
1, 2, 3, and at weeks 1, 4 (Table S7), respectively, indicating that patients would be 1.6 times more likely to suffer moderate or severe pain at the end of the treatment if they had not taken pinaverium. The RRs for diarrhea
(Bristol scale > 4) was 0.82 (0.72–0.93), 0.81 (0.70–0.92), 0.74 (0.63–0.86), 0.73 (0.60–0.89), and 0.67 (0.53–0.83)
when compared with placebo during the treatment indicating that patients would be 1.5 times more like to suffer
diarrhea if they had not taken pinaverium.
The correlation among the primary and secondary endpoints. The Average Inter-item Correlation (r∑) analysis
indicated that pinaverium tended to relieve all the four symptoms simultaneously (Table S8). The correlations
among the primary and secondary endpoints were gradually increased from moderate on day 1 to strong at
week 4 (r∑ = 0.520–0.914), indicating that pinaverium relieved the four IBS symptoms simultaneously, but some
symptoms were improved faster than others. The strongest correlation existed between one symptom and its
frequency while weak correlation existed between different symptoms (Table S8).

Primary and Secondary outcomes during the post‑treatment. The offset of action. Pinaverium
had a slow offset of action (Fig. 2). Three days after pinaverium was discontinued, the average pain scale rebounded only 42.8% while stool consistencies rebounded 41.2% [(Day 31–Day 28)/(Day 427–Day 28)]. These
3-day rebounds in the secondary endpoints were 23.2% (pain frequency) and 38.3% (stool frequency).
The maintenance of the efficacy after pinaverium was discontinued. The therapeutic effects of pinaverium were
maintained until 9–17 weeks after pinaverium was discontinued. During this PTTE period, the symptomatic
endpoints of the pinaverium group were significantly deceased when compared with those in the placebo group
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402 Patients screened

138 Excluded
41 Refused to participate
58 Did not meet inclusion criteria
24 Met exclusion criteria
15 Declined the commitment for
post-treatment follow up

264 Randomized

Treatment

132 Received pinaverium

31 Missed treatments
14 Symptom relief was not as expected
6 Found the study inconvenient
7 Switched to another treatment
4 Others

Post-treatment

40 Missing follow-ups
19 Missing 1 follow-up
6 Missing 2 follow-ups
4 Missing 3 follow-ups
11 Missing 4 or more follow-ups

Analysis

132 All participants (Intention to treat)
101 Received complete treatment (Per protocol)

132 Intention to treat
92 Per protocol

132 Received placebo

40 Missed treatments
19 Symptom relief was not as expected
9 Found the study inconvenient
6 Switched to another treatment
6 Others

132 All participants (Intention to treat)
92 Received complete treatment (Per protocol)

45 Missing follow-ups
17 Missing 1 follow-up
12 Missing 2 follow-ups
6 Missing 3 follow-ups
10 Missing 4 or more follow-ups

132 Intention to treat
87 Per protocol

Figure 1.  Flowchart of the trial.
(P < 0.05; Fig. 2, Tables S5 and S6), the response rates in the pinaverium group were significantly higher than
those in the placebo group (P < 0.05; Table 2), and the risk that patients suffered moderate or severe symptoms
and the percentages of patients with IBS symptoms in the pinaverium group were significantly lower than those
in the placebo group (P < 0.05; Tables S7 and S9).

Survival (relapse‑free) analysis. Patients whose symptoms were significantly improved at the end of
treatment were used for the Kaplan–Meier survival (relapse-free) analysis (see the Supplemental Materials for
details; pinaverium: n = 85, 72, 88, and 72 for pain, stool consistency, pain frequency, and stool frequency, respectively; placebo: n = 42, 42, 45, and 49). The relapse-free probabilities of all the primary and secondary endpoints
in the pinaverium group were significantly higher than those in the placebo group (Fig. 3A) indicating that the
therapeutic effects of pinaverium extended beyond the treatment.
Among the patients whose global overall symptom scales were significantly improved by the end of the treatment (pinaverium n = 91, placebo n = 49), symptoms relapsed in a total of 41 (45.1%) patients in the pinaverium
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Characteristic

Pinaverium (n = 132)

Placebo (n = 132)

P value

Age, mean ± SD

41.8 ± 14.0

38.9 ± 13.7

0.09
0.71

Male, n (%)

54 (41%)

51 (39%)

Female, n (%)

78 (59%)

81 (61%)

IBS history, years ± SD

4.92 ± 4.42

4.98 ± 3.91

0.91

Abdominal pain, mean ± SD

4.92 ± 1.50

5.03 ± 1.62

0.58

Stool consistency, mean ± SD

6.10 ± 0.83

6.01 ± 0.76

0.35

Pain frequency, mean ± SD

4.66 ± 1.54

4.56 ± 1.54

0.60

Stool frequency, mean ± SD

4.36 ± 1.06

4.15 ± 1.09

0.12

Global overall symptom scale, mean ± SD

2.55 ± 0.89

2.55 ± 0.81

0.94

Table 1.  The baselines of demographics, IBS medical history, and IBS symptoms (intention-to-treat
population). Chi-square for genders; T-test for others.

group while 36 (73.5%) patients of the placebo group by week 57 reconfirming that the therapeutic effects of
pinaverium extended beyond the treatment (P < 0.005, X22 = 10.4). The PTTE of pinaverium could also be seen
in the remarkable distribution differences (Fig. 3B). During first few days after the treatment was discontinued,
relatively more relapses occurred in the placebo group than in the pinaverium group.

Natural history of IBS.

Seventeen weeks after the treatments were discontinued, there were no significant
differences between pinaverium and placebo in terms of all measurements (Fig. 2, Table 2, Supplemental Material Tables S5–S7, and S9). Therefore, the stage after 17 weeks could be considered as IBS natural history. During
this period, an average of 51.5–56.4% of patients (pool pinaverium and placebo data together) had IBS symptoms (pain scale ≥ 3, stool consistency ≥ 5) (Table S9). At the end of this study (week 61), 146 (54.9%) patients
had IBS symptoms.

Tertiary endpoint outcomes. Pinaverium significantly and rapidly reduced the scales of the global overall
symptom from day 1 (P < 0.05; Figure S1). During the first 3 days, the scales reduced 83.4% of the total decrease
reconfirming that pinaverium has a rapid onset of action for relieving IBS symptoms. At the end of the treatment,
68.9% (91 patients) of the pinaverium patients’ global overall symptom scales decreased in contrast to 37.1% (49
patients) in the placebo group (P < 0.001, X22 = 26.8). Pinaverium had a slow offset of action. Three days after
pinaverium was discontinued, the global overall symptom rebounded only accounted for 42.3% of the entire
rebounded scale. The improved global overall symptom was maintained until 9–17 weeks after pinaverium was
discontinued. After week 17, there were no significantly differences between pinaverium and placebo (P < 0.05).
Pearson correlation coefficient analysis revealed that the global overall symptom scales were most strongly
associated to pain during both the treatment and the post-treatment indicating that patients’ global evaluations
were mainly based on the pains they suffered (Table S10, P < 0.01).
No severe treatment-emergent adverse event (TEAE) occurred during this study that limited patients’ activities, required medical intervention or required hospitalization. A total of 23 patients in the pinaverium group
suffered at least 1 TEAEs while 19 patients in placebo group (Table S11). The adverse event profiles of the 2 groups
showed a significant difference (Fisher’s exact test, P < 0.05), indicating that the adverse events in the pinaverium
group were caused by the treatment. Most patients had 1 TEAE. Only four patients in the pinaverium group and
2 patients in the placebo group had 2 TEAEs.
Routine laboratory results, vital signs, physical examinations, and electrocardiograms were unremarkable
showing no treatment-related effects.

Discussion

In this trial, we developed a 3-element criterion to study pinaverium’s PTTE, relapse-free probability, and IBS
natural history. First, pinaverium effectively relieved IBS symptoms so that the PTTE was justified due to the
treatment. Second, the follow-up duration of current trial lasted 57 weeks covering both the PTTE period and
the natural history thereafter. The natural history is defined as the period in which no significant differences
in the outcome endpoints between the treatment group and the placebo group. Third, we collected data at an
adequate data collection resolution (we collected data 10 times during the follow-up period). Our results showed
that the significant differences between the outcomes of pinaverium and placebo disappeared between weeks
9 and 17 after the treatment was discontinued (P > 0.05, Fig. 2, Table 2, Supplemental Material Tables S7, S9).
We concluded that pinaverium PTTE lasted 9–17 weeks. The stage after week 17 could be considered as IBS
natural history.
It is important to cover the IBS natural history when assessing PTTE. First, roughly half of patients could
recover without any treatment after 1 and 7 years2. To distinguish the PTTE from IBS natural history, PTTE
studies should collect outcome data during both PTTE period and IBS natural history. Second, the percentage of
patients with IBS symptoms during IBS natural history is an important clinical parameter for the study populations. In the present study, 51.5–56.4% of patients suffered IBS symptoms during the 40-week natural history
(weeks 17–57) (Table S9). Our results were consistent with previous studies that approximately half of the patients
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5
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6
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5
4
3
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400

0
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Normalized 6 endpoints

Days

1.0

300

400

Days

Y = 0.80 + 0.19e-0.52X

0.87

Y=

0.9

1+e

-

0.86

Y=
1+e

X - 21.13
3.09

-

Pinaverium
Control

X - 27.92
0.98

0.8
0.7

0.87

Y=

0.6

Y = 0.65 + 0.34e-0.84X

0.5
0

4

8

0.75

Y=
1+e
28

32

-

100

1+e

X - 23.98
2.46

200

300

-

X + 170.05
126.95

400

Days
Figure 2.  The time course of the endpoints during the treatment and post-treatment (intention-to-treat
population; n = 132 for each group). Error bars indicate 95% confidence intervals. The numeric values of the
endpoints were listed in Supplemental Material Tables S5 (intention-to-treat population) and S6 (per-protocol
population). The t test comparing pinaverium with placebo is indicated by * (P < 0.05). Bottom panel: Responses
of each endpoint during the treatment and post-treatment were normalized.

had unchanged or aggravated symptoms after 5 y ears24, and “patients with unchanged symptoms (30–50%) and
patients whose symptoms had worsened (2–18%)” after 6 y ears25.
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Primary endpoints
Pain

Secondary endpoints
Stool consistency

Res%

OR (95% Cl) P
(X22)

Pinaverium

52.3

Placebo

17.4

Res%

OR (95% Cl) P
(X22)

5.19

28.8

(2.5–9.13)

12.9

Pain frequency

Stool frequency

Res%

OR (95% Cl) P
(X22)

Res%

OR (95% Cl) P
(X22)

2.73

44.7

3.46

28.0

1.97

(1.45–5.15)

18.9

(1.99–6.02)

16.5

TREATMENT
Day 1

< 0.001 (35.3)

< 0.005 (10.1)

< 0.001 (20.2)

(1.08–3.57)
< 0.05 (5.0)

Day 2
Pinaverium

54.5

3.91

31.8

2.68

50.8

2.75

42.4

Placebo

23.5

(2.30–6.63)

14.4

(1.46–4.93)

27.3

(1.65–4.59)

20.5

< 0.001 (26.8)

< 0.005 (10.4)

< 0.001 (15.3)

2.86
(1.66–4.94)
< 0.001 (14.8)

Day 3
Pinaverium

60.6

3.67

37.9

3.22

56.8

3.95

42.4

Placebo

29.5

(2.20–6.12)

15.9

(1.80–5.78)

25.0

(2.34–6.66)

26.0

< 0.001 (25.7)

< 0.001 (16.2)

< 0.001 (27.6)

2.10
(1.25–3.53)
< 0.005 (7.9)

Week 1
Pinaverium

53.8

2.68

47.7

2.26

60.6

2.88

47.0

Placebo

30.3

(1.62–4.44)

28.8

(1.36–3.76)

34.8

(1.74–4.74)

29.9

< 0.001 (14.9)

< 0.005 (10.0)

< 0.001 (17.6)

2.07
(1.25–3.44)
< 0.005 (8.1)

Week 4
Pinaverium

64.4

3.88

54.5

2.57

66.7

3.87

54.5

Placebo

31.8

(2.32–6.46)

31.8

(1.56–4.25)

34.1

(2.32–6.44)

38.6

< 0.001 (28.1)

< 0.001 (13.9)

< 0.001 (28.0)

1.91
(1.17–3.12)
< 0.010 (6.8)

POST-TREATMENT
Day 1
Pinaverium

62.3

4.04

58.3

3.11

65.2

4.15

58.3

2.09

Placebo

29.5

(2.42–6.76)

31.1

(1.87–5.15)

31.1

(2.48–6.94)

40.2

(1.28–3.41)

< 0.001 (29.5)

< 0.001 (19.9)

< 0.001 (30.7)

< 0.005 (8.7)

Day 2
Pinaverium

62.1

4.37

56.8

3.25

63.6

4.33

59.1

2.22

Placebo

27.3

(2.60–7.36)

28.8

(1.95–5.42)

28.8

(2.58–7.26)

39.4

(1.36–3.64)

< 0.001 (32.4)

< 0.001 (21.1)

< 0.001 (32.2)

< 0.005 (10.3)

Day 3
Pinaverium

62.1

4.21

54.5

2.66

63.6

4.03

55.3

2.11

Placebo

28.0

(2.51–7.07)

31.1

(1.61–4.41)

30.3

(2.41–6.73)

37.0

(1.29–3.45)

< 0.001 (31.0)

< 0.001 (14.9)

< 0.001 (29.4)

< 0.005 (8.9)

Week 4
Pinaverium

56.8

2.63

47.0

1.71

59.8

3.31

53.0

2.21

Placebo

33.3

(1.60–4.34)

34.1

(1.04–2.81)

31.1

(1.99–5.49)

33.9

(1.34–3.62)

< 0.001 (14.7)

< 0.05 (4.5)

< 0.001 (22.1)

< 0.005 (9.9)

Week 9
Pinaverium

50.8

1.69

50.0

1.69

49.2

1.64

49.2

1.77

Placebo

37.9

(1.04–2.76)

37.1

(1.04–2.77)

37.1

(1.01–2.69)

35.4

(1.08–2.90)

< 0.05 (4.5)

< 0.05 (4.5)

< 0.05 (4.0)

< 0.05 (5.2)

Week 17
Pinaverium

43.9

1.47

47.0

1.55

47.0

1.55

45.5

1.37

Placebo

34.8

(0.89–2.41)

36.4

(0.95–2.54)

36.4

(0.95–2.54)

37.8

(0.84–2.24)

> 0.05 (2.3)

> 0.05 (3.1)

> 0.05 (3.1)

> 0.05 (1.6)

Week 25
Pinaverium

45.5

1.56

43.9

1.47

46.2

1.55

41.7

1.30

Placebo

34.8

(0.95–2.56)

34.8

(0.89–2.41)

35.6

(0.95–2.55)

35.4

(0.79–2.14)

> 0.05 (3.1)

> 0.05 (2.3)

> 0.05 (3.1)

> 0.05 (1.1)

Week 33
Pinaverium

40.2

1.34

41.7

1.59

43.2

1.57

42.4

1.44

Placebo

33.3

(0.81–2.22)

31.1

(0.96–2.63)

32.6

(0.95–2.60)

33.9

(0.87–2.37)

> 0.05 (1.3)

> 0.05 (3.2)

> 0.05 (3.2)

> 0.05 (2.1)

Continued
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Primary endpoints
Pain
Res%

Secondary endpoints
Stool consistency

OR (95% Cl) P
(X22)

Res%

OR (95% Cl) P
(X22)

Pain frequency
Res%

OR (95% Cl) P
(X22)

Stool frequency
Res%

OR (95% Cl) P
(X22)

Week 45
Pinaverium

38.6

1.07

43.9

1.57

40.9

1.38

40.9

1.31

Placebo

37.1

(0.65–1.75)

33.3

(0.95–2.58)

33.3

(0.84–2.29)

34.6

(0.79–2.15)

> 0.05 (0.1)

> 0.05 (3.1)

> 0.05 (1.6)

> 0.05 (1.1)

Week 57
Pinaverium

37.1

1.10

40.9

1.29

39.4

1.30

42.4

1.30

Placebo

34.8

(0.67–1.82)

34.8

(0.76–2.13)

33.3

(0.79–2.15)

36.2

(0.79–2.13)

> 0.05 (0.1)

> 0.05 (1.0)

> 0.05 (1.0)

> 0.05 (1.1)

Table 2.  Efficacy of the treatment measured by endpoint symptoms (the response rates, odds ratios (OR), and
95% confidence interval (CI)) in the intention-to-treat population). Res% response rates.

In contrast, none of the existing trials met the 3-element criterion. The existing trials drew inaccurate or
misleading conclusions regarding the PTTE durations. Critical thinking is needed to correctly interpret the
results from these existing studies26. For example, Pimentel et al. only followed up with patients for 10 weeks after
rifaximin was discontinued, and the rifaximin group still showed significantly improved symptoms at week 10
when the trial ended (P < 0.05)4. Pimentel et al. concluded, “Rifaximin improves IBS symptoms for up to 10 weeks
after the discontinuation of therapy.” This is not accurate because “the significantly improved symptoms” might
still last beyond 10 weeks. Accordingly, the Editorial Comment on this study is incomplete (“Over a 10-week
follow-up period, the rifaximin recipients reported global improvements in overall symptoms and less bloating
more frequently than the placebo recipients”27) although this comment is correct by itself. An accurate conclusion would be that rifaximin could improve IBS symptoms for at least 10 weeks after the discontinuation of
therapy. Indeed, some researchers have already noticed this inaccuracy, and suggested that “further randomized
controlled trials with active control conditions and longer-term follow-up are needed to determine the effect
of such a [treatment]”28, and recently, more trials included post-treatment analyses as an essential part though
they did not meet the above 3 element criterion (Table S2, trails in italic).
Nevertheless, the preliminary data from these existing studies suggested the treatment-dependency of PTTE
(Table 3). In particular, CBT had the longest PTTE (roughly one year or so), while 5-HT3 antagonist, alosetron,
the shortest (less than one week), and antidepressants have 4 weeks to 1 year P
 TTE7,8.
Heitkemper et al. showed that patients in both 8-week psychotherapy and 1-day psychotherapy showed significant PTTE one year after the psychotherapy (P < 0.05)9. Lackneret al. showed that both patient-administered
CBT and therapist-administered CBT significantly improved IBS symptoms when compared with the control
2 weeks after the 10-week treatments (P < 0.05)10. Jarrettet al. showed that the psychotherapy was “efficacious
whether delivered primarily by telephone or totally in-person” one year after the therapy11. Everitt et al. showed
that both telephone and web “interventions were superior to TAU (the control group) up to 12 months of followup”11. All the above evidence reaffirmed that PTTE is “treatment-dependent” regardless of the length of the
treatment, who administered the treatment, and how the treatment was administered.
The current trial showed that antispasmodics have 9–17 weeks of PTTE in consistence with previous studies
showing that the PTTE of otilonium lasted at least 10 w
 eeks15. That the PTTE in current trial with a 4-week treatment had a similar length to that of Clavé et al. with a 15-week treatment15 indicated that the PTTE in pharmacological therapies less depends on the length of the treatment like that in non-pharmacological therapies or CBT.
The mechanism of the treatment-dependency of PTTE is likely due to the mechanism of action of the treatment. Otilonium and pinaverium are the first two antispasmodics recommended by ACG to manage I BS5, and
both antispasmodics are voltage activated L-type calcium channel blockers49,50. Clavé et al. proposed, “[d]ue
to its lipophylic properties, (otilonium’s) affinity for colonic smooth muscle may extend beyond the treatment
period, and this could explain the prolonged efficacy after cessation of drug intake.”15 We believe that in addition
that the “affinity for colonic smooth muscle may extend beyond the treatment period”, the prolonged efficacy of
pinaverium was also due to the improvement of the function of the colonic smooth muscles during the treatment, and this improvement extended beyond the treatment p
 eriod50–53. This hypothesis is consistent with the
nature of IBS, a functional disorder, and further supported by the results from Camilleri et al., who showed that
the efficacy of alosetron in IBS waned within one week after alosetronwas discontinued45. Alosetron reduces IBS
symptoms through peripheral antinociception and inhibition of emotional motor system regions in the b
 rain54,
both of these mechanisms do not primarily improve the colonic function so that the efficacy of alosetron waned
quickly after the treatmentwas discontinued. It is interesting to note that, in contrast to other treatments, probiotics showed remarkable heterogeneous results. S. cerevisiae has only 1–2 weeks of PTTE while L. plantarum
has at least 1 year of P
 TTE30,31. This heterogeneity is consistent with the evidence that different probiotics benefit
gastrointestinal functions d
 ifferently55.
In addition to not fulfilling the above 3-element criterion, all the existing trials failed to address another
important question, how quickly their therapy took effects. In these trials, the soonest outcome data were collected one week after the therapies were initiated. In this present study, data were collected from the second day
after pinaverium was initiated. With this data collection resolution, our study demonstrated that the decreases
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A
1.0

Pain
Pain frequency
Stool consistency
Stool frequency

Survival (Relapse-free)

Pinaverium
0.8

0.6
Placebo

0.4

0.2
0

100

200
Days

Log rank test (P values):
Pain
0.0018
Stool consistency 0.0079

B

% of relapses

y = 3.20 + 12.63e

400

Pain frequency
Stool frequency

- 0.5

18
16
14
12
10
8
6
4
2
0

300

x - 2.42
1.43

0.0132
0.0005

2

Pinaverium
Placebo

- 0.5
y = 0.73 + 6.18e

x - 4.70
2.60

2

*
*
*

Post-treatment
Figure 3.  (A) Kaplan–Meier analysis on the relapse-free events as measured by the symptomatic endpoints
(pinaverium: n = 85, 72, 88, and 72 for pain, stool consistency, pain frequency, and stool frequency, respectively;
placebo: n = 42, 42, 45, and 49; see the Supplemental Material). (B). Distributions of relapses as measured by
global overall symptom scales, which were nonlinearly regressed by Gaussian processes. See the Supplemental
Material for details.
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Post-treatment
Follow-up duration

Date collected at

Did the therapeutic effects
last?

1 wk

wk 1

≥ 1 wk

29

S. cerevisiae

3 wk

Every wk

1–2 wk

30

L. plantarum

12 mo

mo 12

≥ 12 mo

31

Treatment

References

Diet
Low FODMAP diet
Probiotics

Antibiotics
10 wka

Every wk

≥ 10 wk

13

10 wk

Every wk

≥ 10 wk

4

3 mo

Every wk

≥ 3 mo

32

Phloroglucinol

1 wk

wk 1

≥ 1 wk

33

Otilonium

10 wk

wk 3, 6, 10

≥ 10 wk

15

pinaverium

57 wk

dy 1, 2, 3, wk 4, 9, 17, 25 ,33,
45, 57

between 9 and 17 wk

Current study

Anise oil

2 wk

wk 2

≥ 2 wk

34

Peppermint oil

4 wk

wk 4

≥ 4 wk

6

Fluoxetine

4 wk

wk 4

≥ 4 wk

7

Paroxetine 20 mg, QD

1 yr

yr 1

< 1 yr (very low DCR)

8

Cognitive behavior therapy

2 wk

wk 2

≥ 2 wk

10

Mindfulness-based cognitive
therapy

6 wk

wk 6

≥ 6 wk

35

Cognitive-based tx

3 mo

mo 3

≥ 3 mo

36

Cognitive-behavioral group
therapy

3 mo

mo 3

≥ 3 mo

27

Mindfulness-based stress and
pain management

3 mo

After tx, mo 3

≥ 3 mo

37

Relaxation response meditation 3 mo

wk 2, mo 3

≥ 3 mo

38

Cognitive-behavioral internet
therapy

3 mo

wk 6, mo 3

≥ 3 mo

39

Cognitive behavioral therapy

3 mo

wk 1, 2, 3, mo 3

≥ 3 mo

40

Telephone/web CBT

4 mo

mo 4

≥ 4 mo

11

Behavioral treatment

5 mo

mo 5

≥ 5 mo

41

Cognitive behavioral therapy

6 mo

mo 2, 3, 6

≥ 6 mo

42

Mindfulness-based stress
reduction

6 mo

mo 6

< 6 mo (low DCR)

28

Psychodynamic inter-personal
therapy

1 yr

yr 1

< 1 yr (very low DCR)

8

Rifaximin
Antispasmodics

Peppermint oil

Antidepressants

Psychological therapies

Hypnotherapy

1 yr

mo 3, yr 1

≥ 1 yr

43

Comprehensive self-management

1 yr

mo 3, 6, 12

≥ 1 yr

11

Comp CBT: 8 wkly 1 h
Brief CBT: one 90 min

12 mo

wk 9, mo 6, 12

≥ 1 yr

9

2 wk

Every wk

< 1 wk

44

4 wk

Every wk

< 1 wk

45–47

1 mo

mo 1

< 1 mo

48

5-HT3 antagonist
Alosetron, 1 mg, BID

Table 3.  Treatment-dependency of post-treatment therapeutic effects. Regular font: The trials reviewed
by Ford et al.5. Italic font: updated studies not reviewed by the American College of Gastroenterology. CBT
cognitive behavior therapy, Comp comprehensive, DCR data collection resolution; dy day(s), FODMAP
fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; mo month(s), QD every day,
yr year. a Repeated treatment design: 2 wk of first rifaximin treatment + 10 wk follow-up + 2 wk of second
rifaximin treatment + 4 wk follow-up. Data from the first treatment and the first follow-up were used here.
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in the outcome scales during the first 3 days of treatment accounted for 75.5–94.5% of the total decreases. The
fast onset of action might be because the lipophilic properties of pinaverium render a high affinity for colonic
smooth muscle15. Our results justified pinaverium being used as a first line rescue medication.
Assessing the onset of action, establishing PTTE, and accurately assessing the length of PTTE are clinically
important for efficient long-term IBS management. Our results provide important insights into cost-effective
management of refractory IBS. For example, for patients with refractory IBS, a therapy with a longer PTTE
should be initiated while for patients who have an urgent need to improve their IBS symptoms, a medication
with a fast onset of action is preferred.
In conclusion, the PTTE of IBS therapy is treatment-dependent. The PTTE of pinaverium lasted 9–17 weeks
in contrast to ≥ 1 year PTTE in CBT and < 1 week PTTE in 5-HT3 antagonist (alosetron) treatment. PTTE length
less depends on the treatment length. The selection of a treatment should consider both its effectiveness during
treatment and its PTTE after treatment. Pinaverium can be used as a first line rescue medication for a quick
symptom relief plus a 9–17 week long PTTE.
Received: 9 December 2020; Accepted: 9 June 2021
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